Spruce Biosciences, Inc. (SPRB)
NASDAQ$0.3351
Market Cap
$13.84M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
854 of 924
Rank in Industry
486 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
SPRB Insider Trading Activity
SPRB Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $1,709,755 | 4 | 100 |
Related Transactions
| Novo Holdings A/S | 10 percent owner | 0 | $0 | 5 | $3.41M | $-3.41M |
About Spruce Biosciences, Inc.
Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for adult patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction and clinical consequences in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for …
Insider Activity of Spruce Biosciences, Inc.
Over the last 12 months, insiders at Spruce Biosciences, Inc. have bought $0 and sold $1.71M worth of Spruce Biosciences, Inc. stock.
On average, over the past 5 years, insiders at Spruce Biosciences, Inc. have bought $19.12M and sold $3.41M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 2,208,000 shares for transaction amount of $7M was made by Novo Holdings A/S (10 percent owner) on 2023‑02‑16.
List of Insider Buy and Sell Transactions, Spruce Biosciences, Inc.
| 2024-03-21 | Sale | Novo Holdings A/S | 10 percent owner | 465,021 1.1289% | $0.75 | $350,951 | -33.85% | |
| 2024-03-20 | Sale | Novo Holdings A/S | 10 percent owner | 359,979 0.8709% | $0.73 | $264,081 | -32.89% | |
| 2024-03-19 | Sale | Novo Holdings A/S | 10 percent owner | 593,000 1.4693% | $0.76 | $447,715 | -33.23% | |
| 2024-03-18 | Sale | Novo Holdings A/S | 10 percent owner | 842,020 2.0939% | $0.77 | $647,008 | -33.48% | |
| 2024-03-14 | Sale | Novo Holdings A/S | 10 percent owner | 1.91M 0.8272% | $0.89 | $1.7M | -37.01% | |
| 2023-02-16 | Novo Holdings A/S | 10 percent owner | 2.21M 0.0087% | $3.17 | $7M | -11.16% | ||
| 2023-02-16 | O'Donnell Niall | director | 630,400 0.0025% | $3.17 | $2M | -11.16% | ||
| 2021-05-20 | Sale | SIMPSON CAMILLA V | director | 334 0.0014% | $15.29 | $5,107 | -71.33% | |
| 2021-05-19 | Sale | Novo Holdings A/S | 10 percent owner | 475,000 1.8365% | $13.90 | $6.6M | -71.51% | |
| 2021-04-30 | Sale | SIMPSON CAMILLA V | director | 14,045 0.06% | $16.14 | $226,664 | -71.70% | |
| 2020-10-14 | Novo Holdings A/S | 10 percent owner | 250,000 0.9752% | $15.00 | $3.75M | -10.92% | ||
| 2020-10-14 | Omega Fund VI, L.P. | 250,000 0.9752% | $15.00 | $3.75M | -10.92% | |||
| 2020-10-14 | Chaya Moghrabi Dina | director | 250,000 0.9752% | $15.00 | $3.75M | -10.92% | ||
| 2020-10-14 | RiverVest Venture Fund III, L.P. | 10 percent owner | 250,000 0.9752% | $15.00 | $3.75M | -10.92% | ||
| 2020-10-14 | HealthCap VIII, L.P. | 250,000 0.9752% | $15.00 | $3.75M | -10.92% | |||
| 2020-10-14 | HANSSON JONAS | director | 250,000 0.9752% | $15.00 | $3.75M | -10.92% | ||
| 2020-10-14 | Muralidhar Bali | director | 200,000 0.7802% | $15.00 | $3M | -10.92% | ||
| 2020-10-14 | O'Donnell Niall | director | 250,000 0.9752% | $15.00 | $3.75M | -10.92% |
Total: 18
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Novo Holdings A/S | 10 percent owner | 2550000 6.1739% | $854,505.00 | 2 | 6 | <0.0001% |
| Omega Fund VI, L.P. | 2161022 5.2322% | $724,158.47 | 1 | 0 | <0.0001% | |
| Chaya Moghrabi Dina | director | 2161022 5.2322% | $724,158.47 | 1 | 0 | <0.0001% |
| RiverVest Venture Fund III, L.P. | 10 percent owner | 2148281 5.2013% | $719,888.96 | 1 | 0 | <0.0001% |
| HealthCap VIII, L.P. | 2033621 4.9237% | $681,466.40 | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$1,724,269 | 63 | -16.36% | $12.25M | |
$8,900,811 | 57 | -24.79% | $15.15M | |
$383,884 | 32 | -25.10% | $12.65M | |
$4,368,362 | 28 | -22.35% | $14.54M | |
$550,893 | 22 | -22.12% | $15M |
SPRB Institutional Investors: Active Positions
| Increased Positions | 11 | +28.95% | 2M | +11.11% |
| Decreased Positions | 14 | -36.84% | 1M | -7.41% |
| New Positions | 6 | New | 1M | New |
| Sold Out Positions | 4 | Sold Out | 492,950 | Sold Out |
| Total Postitions | 35 | -7.89% | 14M | +3.69% |
SPRB Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Rivervest Venture Management Llc | $1,142.00 | 7.16% | 2.94M | 0 | 0% | 2024-09-30 |
| Carlyle Group Inc. | $1,127.00 | 7.07% | 2.9M | 0 | 0% | 2024-12-31 |
| Rock Springs Capital Management Lp | $1,015.00 | 6.36% | 2.61M | 0 | 0% | 2024-12-31 |
| Acadian Asset Management Llc | $407.00 | 2.55% | 1.05M | -213,323 | -16.94% | 2024-12-31 |
| Ikarian Capital, Llc | $389.00 | 2.44% | 1M | +1M | New | 2024-12-31 |
| Vanguard Group Inc | $328.00 | 2.06% | 843,844 | 0 | 0% | 2024-12-31 |
| Sands Capital Ventures, Llc | $278.00 | 1.75% | 715,817 | -71,190 | -9.05% | 2024-12-31 |
| Renaissance Technologies Llc | $158.00 | 0.99% | 405,900 | -203,800 | -33.43% | 2024-12-31 |
| Adar1 Capital Management, Llc | $157.00 | 0.99% | 403,716 | 0 | 0% | 2024-12-31 |
| Boothbay Fund Management, Llc | $112.00 | 0.7% | 288,800 | +288,800 | New | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.